PATENT CLAIM ANALYSIS

Application Number: 16246380
Application Type: Utility
Filing Date: 2019-01
Publication Date: 2019-05
Patent Classification: ["514", "259000"]

Abstract:
A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R 1 , R 2 , R 3 , R 4 , R 5 , and n are as defined herein.

Claim (Index 20):
The use of  claim 19 , wherein said disease or disorder is selected from diffused large B cell lymphoma, follicular lymphoma, other lymphomas, leukemia, multiple myeloma, mesothelioma, gastric cancer, malignant rhabdoid tumor, hepatocellular carcinoma, prostate cancer, breast carcinoma, bile duct and gallbladder cancers, bladder carcinoma, brain tumors including neuroblastoma, schwannoma, glioma, glioblastoma and astrocytoma, cervical cancer, colon cancer, melanoma, endometrial cancer, esophageal cancer, head and neck cancer, lung cancer, nasopharyngeal carcinoma, ovarian cancer, pancreatic cancer, renal cell carcinoma, rectal cancer, thyroid cancers, parathyroid tumors, uterine tumors, and soft tissue sarcomas.

Metadata:
- Claim Count in Document: 8.0
- Percentile: 99.0
- Lexical Diversity: 1.27907
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14977273', '15538348', '16311575', '16311621', '16012468']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7996730666521016
- 35 USC 102 Novelty (BERT): 0.5862774539535757
- Combined Prediction Score: 0.778333505382249
- Mean Citation Score: 448.49072400000006
- Max Citation Score: 509.5315
- Similarity Product: 395.6709437356592

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test